Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H JACKSON

Showing results (691-700 of 770) with videos related to

Pageof 77
Sort By:
Scientific Reports|February 12, 2021
Inflammatory profiles in Chilean Mapuche and non-Mapuche women with gallstones at risk of developing gallbladder cancerSarah S Jackson, Vanessa Van De Wyngard, Ruth M Pfeiffer, et al.
Frontiers in Immunology|May 30, 2017
<i>Mycobacterium tuberculosis</i> Induction of Heme Oxygenase-1 Expression Is Dependent on Oxidative Stress and Reflects Treatment OutcomesNeesha Rockwood, Diego L Costa, Eduardo P Amaral, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX StudyAndy C Rawstron, J Anthony Child, Ruth M de Tute, et al.
British Journal of Haematology|December 21, 2022
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trialMatthew W Jenner, Charlotte Pawlyn, Faith E Davies, et al.
Eclinicalmedicine|August 9, 2023
Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI TrialJohn R Jones, David A Cairns, Tom Menzies, et al.
Blood Advances|May 24, 2018
Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductaseSarah E Fordham, Helen J Blair, Claire J Elstob, et al.
Leukemia|August 13, 2011
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trialK D Boyd, F M Ross, L Chiecchio, et al.
Blood|October 25, 2011
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysisGareth J Morgan, Walter M Gregory, Faith E Davies, et al.
Lancet (London, England)|December 7, 2010
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Blood|May 22, 2020
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trialsCharlotte A Bradbury, Zoe Craig, Gordon Cook, et al.
Pageof 77

Showing results (691-700 of 770) with videos related to

Sort By:
Pageof 77
Scientific Reports|February 12, 2021
Inflammatory profiles in Chilean Mapuche and non-Mapuche women with gallstones at risk of developing gallbladder cancerSarah S Jackson, Vanessa Van De Wyngard, Ruth M Pfeiffer, et al.
Frontiers in Immunology|May 30, 2017
<i>Mycobacterium tuberculosis</i> Induction of Heme Oxygenase-1 Expression Is Dependent on Oxidative Stress and Reflects Treatment OutcomesNeesha Rockwood, Diego L Costa, Eduardo P Amaral, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX StudyAndy C Rawstron, J Anthony Child, Ruth M de Tute, et al.
British Journal of Haematology|December 21, 2022
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trialMatthew W Jenner, Charlotte Pawlyn, Faith E Davies, et al.
Eclinicalmedicine|August 9, 2023
Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI TrialJohn R Jones, David A Cairns, Tom Menzies, et al.
Blood Advances|May 24, 2018
Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductaseSarah E Fordham, Helen J Blair, Claire J Elstob, et al.
Leukemia|August 13, 2011
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trialK D Boyd, F M Ross, L Chiecchio, et al.
Blood|October 25, 2011
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysisGareth J Morgan, Walter M Gregory, Faith E Davies, et al.
Lancet (London, England)|December 7, 2010
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Blood|May 22, 2020
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trialsCharlotte A Bradbury, Zoe Craig, Gordon Cook, et al.
Pageof 77